Medicenna Historical Income Statement
| MDNA Stock | CAD 1.72 0.06 3.37% |
Historical analysis of Medicenna Therapeutics income statement accounts such as Total Revenue of 0.0 can show how well Medicenna Therapeutics Corp performed in making a profits. Evaluating Medicenna Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Medicenna Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Medicenna Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Medicenna Therapeutics is a good buy for the upcoming year.
Medicenna |
About Medicenna Income Statement Analysis
Medicenna Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Medicenna Therapeutics shareholders. The income statement also shows Medicenna investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Medicenna Therapeutics Income Statement Chart
Add Fundamental
Total Revenue
Total revenue comprises all receipts Medicenna Therapeutics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Medicenna Therapeutics. It is also known as Medicenna Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Interest Income
Income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments.Most accounts from Medicenna Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Medicenna Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Medicenna Therapeutics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At this time, Medicenna Therapeutics' Interest Expense is very stable compared to the past year. As of the 30th of November 2024, Net Interest Income is likely to grow to about 1.3 M, while Depreciation And Amortization is likely to drop 4,275.
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Income | 69K | 6.3M | 1.2M | 1.2M | Net Interest Income | 69K | 914K | 1.2M | 1.3M |
Medicenna Therapeutics income statement Correlations
Click cells to compare fundamentals
Medicenna Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Medicenna Therapeutics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 7.9K | 40K | 38K | 5K | 4.5K | 4.3K | |
| Selling General Administrative | 2.5M | 6.5M | 7.7M | 7.0M | 7.9M | 4.2M | |
| Gross Profit | (7.9K) | (40K) | (38K) | (5K) | (4.5K) | (4.7K) | |
| Other Operating Expenses | 8.2M | 17.4M | 22.5M | 16.3M | 19.7M | 10.7M | |
| Operating Income | (8.2M) | (17.2M) | (22.3M) | (21.6M) | (19.7M) | (18.7M) | |
| Net Income From Continuing Ops | (8.3M) | (17.3M) | (22.6M) | (10.0M) | (25.5M) | (24.2M) | |
| Ebit | (8.3M) | (17.3M) | (22.6M) | (16.3M) | (18.7M) | (17.7M) | |
| Research Development | 5.9M | 10.9M | 14.7M | 9.3M | 11.8M | 6.7M | |
| Ebitda | (8.3M) | (17.2M) | (22.5M) | (16.3M) | (18.7M) | (17.7M) | |
| Cost Of Revenue | 7.9K | 40K | 38K | 5K | 5.8K | 5.5K | |
| Total Operating Expenses | 8.2M | 17.4M | 22.5M | 16.3M | 19.7M | 10.7M | |
| Income Before Tax | (8.3M) | (17.3M) | (22.6M) | (10.0M) | (25.5M) | (24.2M) | |
| Total Other Income Expense Net | 919K | 106K | 1.6M | 7.0M | (5.8M) | (5.5M) | |
| Net Income Applicable To Common Shares | (8.3M) | (17.3M) | (22.6M) | (10.0M) | (9.0M) | (9.5M) | |
| Net Income | (8.3M) | (17.2M) | (22.6M) | 1.5M | (25.5M) | (24.2M) | |
| Income Tax Expense | 32.3K | (106K) | 69K | (11.6M) | (10.4M) | (9.9M) | |
| Net Interest Income | 6.7K | 314K | 69K | 914K | 1.2M | 1.3M | |
| Interest Income | 32.3K | 106K | 69K | 6.3M | 1.2M | 1.2M | |
| Reconciled Depreciation | 7.9K | 40K | 38K | 4K | 4.6K | 4.4K |
Pair Trading with Medicenna Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Medicenna Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medicenna Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Medicenna Stock
The ability to find closely correlated positions to Medicenna Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Medicenna Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Medicenna Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Medicenna Therapeutics Corp to buy it.
The correlation of Medicenna Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Medicenna Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Medicenna Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Medicenna Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Medicenna Stock
Medicenna Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Medicenna Therapeutics shareholders. The income statement also shows Medicenna investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).